The European Heart Rhythm Association (EHRA) and the German Atrial Fibrillation Competence NETwork (AFNET), have scheduled the 6th AFNET/EHRA consensus conference to discuss on "Integrating new approaches to atrial fibrillation in an era of digital evolution ".
Venue: The European Heart House, Sophia-Antipolis (France)Dates: 18 & 19 January 2017
Please read here the final programme.
Prof. Günter Breithardt, Münster, GermanyProf. A. John Camm, London, UKProf. Paulus Kirchhof, Birmingham, UK / Münster, GermanyProf. Gregory Y. H. Lip, Birmingham, UKProf. Ulrich Schotten, Maastricht, The Netherlands
More than 80 specialists in atrial fibrillation – invited scientists from 16 European countries, the USA, Canada and Australia, as well as industry representatives from 8 companies – participated in the 6th Joint AFNET/EHRA consensus conference.The two-day expert meeting started with presentations in a plenary session (See programme). Thereafter, participants split into smaller groups (See below the special issues discussed in the break-out sessions). The results of these workshops were discussed in two additional plenaries to achieve consensus on the main results of the conference. The results of the conference are going to be published in a consensus report.
Detection of AF – the next frontier (population / high-risk patients screening, the validity of consumer products for AF detection, public health implications of screening for stroke prevention and beyond). What are the psychological problems to be overcome in early disease prevention, screening, etc.? Experience from other fields of medicine?Integrated management of AF – opportunities and limitations. The role of nurses and other specialities, use and evaluation of IT tools, patient centred approaches, etc. Innovation for better and more efficient AF management, or “nice to have”? AF as a disease within the broad risk factor burden of cardiovascular disease may require approaches that integrate AF into the “25 to 25” programme of the WHF/WHO.Stroke prevention in AF – exploring the boundaries in multidisciplinary approaches (discontinuation of therapy, what to do in patients who bleed or have a stroke on anticoagulation, low-risk patients, biomarkers for stroke and bleeding, LAA occluders, is the link between bleeding events and death mediated by stopping anticoagulation)Rate control – back to basics (role of digoxin, targets for rate control)Rhythm control therapy for different types of AF - Should we abandon the “paroxysmal – persistent” differentiation and integrate markers for the major drivers of AF into our management algorithms? (genes, biomarkers, ECG markers, clinical conditions). Can this guide rhythm control therapy decisions now or in the future (antiarrhythmic drug selection, cryo balloon ablation, AF ablation “beyond PVI”, combination therapy, how to measure improvements in safety)?The AF Heart Teams - When and how are they useful (e.g. complex stroke prevention, complex rhythm control), and which expertise is required?
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved